Evidence map›Paper›PMID 36350899›Full record

ArticlePloS one2022

Experiences of participants in a clinical trial of a novel radioactive treatment for advanced prostate cancer: A nested, qualitative longitudinal study.

Bianca Viljoen, Michael S Hofman, Suzanne K Chambers, Jeff Dunn, Haryana M Dhillon, Ian D Davis, Nicholas Ralph

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03392428 (TheraP), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03392428 phase2completednot on this map

TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)

TypeinterventionalSponsorAustralian and New Zealand Urogenital and Prostate Cancer Trials GroupRan2018 to 2021Enrolled201ConditionsCancer of the Prostate, Metastatic CancerArms177Lu-PSMA617, Cabazitaxel
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Bianca ViljoenSchool of Nursing & Midwifery, University of Southern Queensland, Toowoomba, Queensland, Australia.ORCID 0000-0003-3412-2607
Michael S HofmanProstate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
Suzanne K ChambersCentre for Health Research, University of Southern Queensland, Springfield, Queensland, Australia.
Jeff DunnCentre for Health Research, University of Southern Queensland, Springfield, Queensland, Australia.
Haryana M DhillonCentre for Medical Psychology and Evidence-based Decision-making (CeMPED), School of Psychology, Faculty of Science, The University of Sydney, Sydney, Victoria, Australia.
Ian D DavisEastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0002-9066-8244
Nicholas RalphSchool of Nursing & Midwifery, University of Southern Queensland, Toowoomba, Queensland, Australia.ORCID 0000-0002-7404-9996
University of Southern Queensland · AUEastern Health · AUEdith Cowan University · AUProstate Cancer Foundation of Australia · AUThe University of Melbourne · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesQualitative studies nested within clinical trials can provide insight into the treatment experience, how this evolves over time and where improved supportive care is required. The purpose of this qualitative study is to describe the lived experiences of men with advanced prostate cancer participating in the TheraP trial; a randomised trial of 177Lu-PSMA-617 compared with cabazitaxel chemotherapy.

methodsFifteen men with advanced prostate cancer were recruited from the TheraP clinical trial with interviews conducted at three timepoints during the trial. An interpretative phenomenological approach was used, and interviews analysed using thematic analysis. This research paper reports the results from the mid-point, conclusion and follow up interviews, focusing specifically on participants' experiences of trial participation.

resultsThree themes were identified representing the lived experiences of men with advanced prostate cancer participating in the TheraP trial: (1) facing limited options; (2) anticipating outcomes and (3) coping with health changes.

conclusionsMen who enrol in clinical trial of anti-neoplastic treatments for prostate cancer need targeted psychological and supportive care that includes attention to unique aspects of the experience of having prostate cancer and being in a clinical trial. As part of their trial experience, men with advanced prostate cancer need to be regularly assessed for survivorship needs, fully informed, supported and referred to services for regular care and support across the trajectory of their disease.

trial registrationNCT03392428. Registered on 8 January 2018 (ANZUP1603).

Indexed as

Prostatic NeoplasmsAdaptation, PsychologicalHumansLongitudinal StudiesMaleQualitative ResearchSurvivorship

Identifiers

PMID36350899
PMCPMC9645653
OpenAlexW4308625190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.